Literature DB >> 30103253

Sex differences in the effect of cannabinoid type 1 receptor deletion on locus coeruleus-norepinephrine neurons and corticotropin releasing factor-mediated responses.

Ryan R Wyrofsky1, Beverly A S Reyes1, Daohai Yu2, Lynn G Kirby3, Elisabeth J Van Bockstaele1.   

Abstract

Cannabinoids are capable of modulating mood, arousal, cognition and behavior, in part via their effects on the noradrenergic nucleus locus coeruleus (LC). Dysregulation of LC signaling and norepinephrine (NE) efflux in the medial prefrontal cortex (mPFC) can lead to the development of psychiatric disorders, and CB1r deletion results in alterations of α2- and β1-adrenoceptors in the mPFC, suggestive of increased LC activity. To determine how CB1r deletion alters LC signaling, whole-cell patch-clamp electrophysiology was conducted in LC-NE neurons of male and female wild type (WT) and CB1r-knock out (KO) mice. CB1r deletion caused a significant increase in LC-NE excitability and input resistance in male but not female mice when compared to WT. CB1r deletion also caused adaptations in several indices of noradrenergic function. CB1r/CB2r-KO male mice had a significant increase in cortical NE levels and tyrosine hydroxylase and CRF levels in the LC compared to WT males. CB1r/CB2r-KO female mice showed a significant increase in LC α2-AR levels compared to WT females. To further probe actions of the endocannabinoid system as an anti-stress neuromediator, the effect of CB1r deletion on CRF-induced responses in the LC was investigated. The increase in LC-NE excitability observed in male and female WT mice following CRF (300 nM) bath application was not observed in CB1r-KO mice. These results indicate that cellular adaptations following CB1r deletion cause a disruption in LC-NE signaling in males but not females, suggesting underlying sex differences in compensatory mechanisms in KO mice as well as basal endocannabinoid regulation of LC-NE activity.
© 2018 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  arousal; psychiatric disorders; sex differences; stress

Mesh:

Substances:

Year:  2018        PMID: 30103253      PMCID: PMC6476636          DOI: 10.1111/ejn.14103

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  92 in total

1.  Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats.

Authors:  A Kask; L Rägo; J Harro
Journal:  Brain Res       Date:  1998-03-30       Impact factor: 3.252

2.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

3.  Predator stress engages corticotropin-releasing factor and opioid systems to alter the operating mode of locus coeruleus norepinephrine neurons.

Authors:  Andre L Curtis; Steven C Leiser; Kevin Snyder; Rita J Valentino
Journal:  Neuropharmacology       Date:  2011-12-23       Impact factor: 5.250

4.  Co-localization of the cannabinoid type 1 receptor with corticotropin-releasing factor-containing afferents in the noradrenergic nucleus locus coeruleus: implications for the cognitive limb of the stress response.

Authors:  Ryan R Wyrofsky; Beverly A S Reyes; Elisabeth J Van Bockstaele
Journal:  Brain Struct Funct       Date:  2017-03-02       Impact factor: 3.270

5.  alpha2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals.

Authors:  A Lee; D L Rosin; E J Van Bockstaele
Journal:  Brain Res       Date:  1998-06-08       Impact factor: 3.252

6.  Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents.

Authors:  B A S Reyes; G Drolet; E J Van Bockstaele
Journal:  J Comp Neurol       Date:  2008-06-01       Impact factor: 3.215

Review 7.  Noradrenergic modulation of extinction learning and exposure therapy.

Authors:  Devin Mueller; Shawn P Cahill
Journal:  Behav Brain Res       Date:  2009-12-01       Impact factor: 3.332

Review 8.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

9.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Cannabinoid CB2 receptors: immunohistochemical localization in rat brain.

Authors:  Jian-Ping Gong; Emmanuel S Onaivi; Hiroki Ishiguro; Qing-Rong Liu; Patricia A Tagliaferro; Alicia Brusco; George R Uhl
Journal:  Brain Res       Date:  2006-02-09       Impact factor: 3.252

View more
  4 in total

1.  Modulation of Noradrenergic and Serotonergic Systems by Cannabinoids: Electrophysiological, Neurochemical and Behavioral Evidence.

Authors:  Aitziber Mendiguren; Erik Aostri; Joseba Pineda
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system.

Authors:  Ryan R Wyrofsky; Beverly A S Reyes; Xiao-Yan Zhang; Seema Bhatnagar; Lynn G Kirby; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2019-05-25

3.  Noradrenergic depletion causes sex specific alterations in the endocannabinoid system in the Murine prefrontal cortex.

Authors:  M A Urquhart; J A Ross; B A S Reyes; M Nitikman; S A Thomas; K Mackie; E J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2019-04-10

Review 4.  Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease.

Authors:  Ronnie D Shade; Jennifer A Ross; Elisabeth J Van Bockstaele
Journal:  Front Aging Neurosci       Date:  2022-10-04       Impact factor: 5.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.